Study population
primary kidney disease, fever, epilepsy, pain, dehydration, dysuria, kidney stones, liver or renal dysfunction, metabolic acidosis, depression, gout
URETHRAL STRICTURE, EPILEPSY, PYELONEPHRITIS, DEHYDRATION, KIDNEY STONE, UTI, METABOLIC ACIDOSIS, GOUT, NEUROGENIC BLADDER
Eligible criteria were participants of both sexes, aged 18 years and older, presenting dysuria with scores ≥ 5 points on the pre-treatment categorical scale for the pain symptom (seven-point scale: 1–2: absent; 3–4: mild; 5–6: moderate; 7: severe). Women of childbearing age and who were sexually active had to be using safe contraceptive methods and had to present a negative pregnancy test before inclusion.Participants were not included if they were pregnant or breastfeeding, had a history of sensitivity to any of the components of the test drug or comparator, presented fever (axillary T°: ≥ 38.5ºC) with dorsal or lumbar pain, kidney stones, urethral stricture, primary kidney disease, neurogenic bladder, or complicated UTI. Other exclusion criteria were deficiency of the enzyme glucose-6-phosphate-dehydrogenase, severe dehydration, metabolic acidosis or gout, pyelonephritis, use of serotonergic or antimicrobial drug within 7 days before the beginning of the study. Participants were also not included if they had any condition that prevented them from participating in the study because of health-related problems (epilepsy, depression, severe liver or renal dysfunction) or according to the investigators’ evaluation, as well as those who had participated in clinical study protocols in the last 12 months.